Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study

This study evaluated the efficacy and safety of tadalafil in pediatric patients with pulmonary arterial hypertension. This phase-3, international, randomized, multicenter (24 weeks double-blind placebo-controlled period; two-year, open-labeled extension period), add-on (patient’s current endothelin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dunbar Ivy, Damien Bonnet, Rolf MF Berger, Gisela M.B. Meyer, Simin Baygani, Baohui Li
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Acceso en línea:https://doaj.org/article/75942800a8a54901aee6b5024833fa15
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:75942800a8a54901aee6b5024833fa15
record_format dspace
spelling oai:doaj.org-article:75942800a8a54901aee6b5024833fa152021-12-01T15:33:19ZEfficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study2045-894010.1177/20458940211024955https://doaj.org/article/75942800a8a54901aee6b5024833fa152021-06-01T00:00:00Zhttps://doi.org/10.1177/20458940211024955https://doaj.org/toc/2045-8940This study evaluated the efficacy and safety of tadalafil in pediatric patients with pulmonary arterial hypertension. This phase-3, international, randomized, multicenter (24 weeks double-blind placebo-controlled period; two-year, open-labeled extension period), add-on (patient’s current endothelin receptor antagonist therapy) study included pediatric patients aged <18 years with pulmonary arterial hypertension. Patients received tadalafil 20 mg or 40 mg based on their weight (heavy-weight: ≥40 kg; middle-weight: ≥25 to <40 kg) or placebo orally once daily for 24 weeks. Primary endpoint was change from baseline in six-minute walk distance in patients aged ≥6 years at Week 24. Sample size was amended from 134 to ≥34 patients, due to serious recruitment challenges. Therefore, statistical significance testing was not performed between treatment groups. Results showed that patient demographics and baseline characteristics ( N  = 35; tadalafil = 17; placebo = 18) were comparable between treatment groups; median age was 14.2 years (6.2–17.9 years) and majority (71.4%, n  = 25) of patients were in the heavy-weight cohort. Least square mean (standard error) changes from baseline in six-minute walk distance at Week 24 was numerically greater with tadalafil versus placebo (60.48 (20.41) vs 36.60 (20.78) meters; placebo-adjusted mean difference (standard deviation) 23.88 (29.11)). Safety of tadalafil treatment was as expected without any new safety concerns. During study Period 1, two patients (one in each group) discontinued due to investigator’s reported clinical worsening, and no deaths were reported. In conclusion, the statistical significance testing was not performed between the treatment groups due to low sample size; however, the study results show positive trend in improvement in non-invasive measurements, commonly utilized by clinicians to evaluate the disease status for children with pulmonary arterial hypertension. Safety of tadalafil treatment was as expected without any new safety signals.Dunbar IvyDamien BonnetRolf MF BergerGisela M.B. MeyerSimin BayganiBaohui Li SAGE PublishingarticleDiseases of the circulatory (Cardiovascular) systemRC666-701Diseases of the respiratory systemRC705-779ENPulmonary Circulation, Vol 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the circulatory (Cardiovascular) system
RC666-701
Diseases of the respiratory system
RC705-779
spellingShingle Diseases of the circulatory (Cardiovascular) system
RC666-701
Diseases of the respiratory system
RC705-779
Dunbar Ivy
Damien Bonnet
Rolf MF Berger
Gisela M.B. Meyer
Simin Baygani
Baohui Li
Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
description This study evaluated the efficacy and safety of tadalafil in pediatric patients with pulmonary arterial hypertension. This phase-3, international, randomized, multicenter (24 weeks double-blind placebo-controlled period; two-year, open-labeled extension period), add-on (patient’s current endothelin receptor antagonist therapy) study included pediatric patients aged <18 years with pulmonary arterial hypertension. Patients received tadalafil 20 mg or 40 mg based on their weight (heavy-weight: ≥40 kg; middle-weight: ≥25 to <40 kg) or placebo orally once daily for 24 weeks. Primary endpoint was change from baseline in six-minute walk distance in patients aged ≥6 years at Week 24. Sample size was amended from 134 to ≥34 patients, due to serious recruitment challenges. Therefore, statistical significance testing was not performed between treatment groups. Results showed that patient demographics and baseline characteristics ( N  = 35; tadalafil = 17; placebo = 18) were comparable between treatment groups; median age was 14.2 years (6.2–17.9 years) and majority (71.4%, n  = 25) of patients were in the heavy-weight cohort. Least square mean (standard error) changes from baseline in six-minute walk distance at Week 24 was numerically greater with tadalafil versus placebo (60.48 (20.41) vs 36.60 (20.78) meters; placebo-adjusted mean difference (standard deviation) 23.88 (29.11)). Safety of tadalafil treatment was as expected without any new safety concerns. During study Period 1, two patients (one in each group) discontinued due to investigator’s reported clinical worsening, and no deaths were reported. In conclusion, the statistical significance testing was not performed between the treatment groups due to low sample size; however, the study results show positive trend in improvement in non-invasive measurements, commonly utilized by clinicians to evaluate the disease status for children with pulmonary arterial hypertension. Safety of tadalafil treatment was as expected without any new safety signals.
format article
author Dunbar Ivy
Damien Bonnet
Rolf MF Berger
Gisela M.B. Meyer
Simin Baygani
Baohui Li
author_facet Dunbar Ivy
Damien Bonnet
Rolf MF Berger
Gisela M.B. Meyer
Simin Baygani
Baohui Li
author_sort Dunbar Ivy
title Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
title_short Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
title_full Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
title_fullStr Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
title_full_unstemmed Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
title_sort efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
publisher SAGE Publishing
publishDate 2021
url https://doaj.org/article/75942800a8a54901aee6b5024833fa15
work_keys_str_mv AT dunbarivy efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT damienbonnet efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT rolfmfberger efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT giselambmeyer efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT siminbaygani efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT baohuili efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
AT efficacyandsafetyoftadalafilinapediatricpopulationwithpulmonaryarterialhypertensionphase3randomizeddoubleblindplacebocontrolledstudy
_version_ 1718404823079976960